What Oleolive does

Oleolive is a privately held biotechnology company headquartered in Shreveport, Louisiana, that develops and commercializes functional molecules derived from olive polyphenols and other sources for therapeutic and consumer wellness applications. The company's core technology platform centers on a proprietary patent-pending extraction process capable of producing up to 95%+ pure oleocanthal (branded as OLIGEN), enabling reproducible, commercial-scale production of one of the most potent olive phenolics for cosmetic, dietary supplement, and therapeutic use. The company operates a research laboratory at Intertech Science Park in Shreveport and runs with 1-10 employees under a leadership team that includes CEO Kiley Grant, COO Dr. Alana Gray, CTO Dr. Jim Cardelli (100+ peer-reviewed publications), and CSO Dr. David Coleman.

The commercial product portfolio comprises Oligen (a standardized olive polyphenol ingredient targeting joint, heart, and healthy aging applications, marketed to B2B ingredient customers through a November 2025 partnership with Applied Food Sciences), SUPER-OLI (a direct-to-consumer high-phenolic skincare oil sold via super-oli.com), and a therapeutic pipeline spanning OL-TL1 (Propentofylline for glioblastoma chemosensitization, with Mayo Clinic), OL-003 (dual PPAR agonist for Alzheimer's disease, with Auburn University), OL-JC1/JC2 (inhalable anti-fibrotic for pulmonary fibrosis), and Agile PRP (lyophilized platelet-rich plasma powder for trauma hemorrhage control). OLIGEN received the first-ever INCI trade name approval for oleocanthal in 2021, and the PRPP process is patented.

Oleolive generates revenue through three streams: B2B ingredient sales and licensing via Applied Food Sciences, direct-to-consumer e-commerce for SUPER-OLI skincare, and non-dilutive research funding through SBIR/STTR grants from the National Cancer Institute, National Institute on Aging, National Heart Lung and Blood Institute, and Department of Defense. The company has secured at least five such grants over 2018-2022, spanning oncology, neurology, fibrosis, and acute care. Pricing for therapeutic candidates and B2B supply agreements is not publicly disclosed. Oleolive is a portfolio company of the Entrepreneurial Accelerator Program.

Name

Oleolive

Legal name

Oleolive, Inc.

Website

https://oleo.live

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Oleolive is a Shreveport, Louisiana-based biotechnology company developing olive polyphenol ingredients (Oligen) and repurposed therapeutic candidates spanning oncology, neurology, fibrosis, and trauma, serving B2B ingredient customers, DTC consumers via SUPER-OLI skincare, and NIH/DoD grant-funded research programs.

Ownership category

akta.pro rank

Product category

Biotechnology Research & Olive Polyphenol Ingredients

NAICS

Starch and Vegetable Fats and Oils Manufacturing (31122), Pharmaceutical and Medicine Manufacturing (3254), Fats and Oils Refining and Blending (311225), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Fats & Oils (2070), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Extracts, Oleoresins & Essential Oils (Spice Extracts for Flavoring) (AFAJANAJ)

akta.pro secondary industries

Olive Oil Production & Bottling (AFAKAEAC), Lipid-Based Emulsions & Encapsulated Oils (Spray-Dried Oils, Microencapsulation) (AFAJALAM), High-Oleic & Specialty Oilseed Oils (AFAJALAC)

Keywords

• Olive polyphenol ingredients
• Therapeutic drug development
• Biotech research platform
• Dietary supplement ingredients
• Cosmetic ingredient supply

Headquarters

HQ city

Shreveport

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Olive Polyphenol Ingredient Sales (Oligen): Oligen, a standardized olive polyphenol ingredient (standardized to oleocanthal and oleacein), is commercialized through a partnership with Applied Food Sciences for joint development, targeting joint health, heart health, and healthy aging applications in food, beverage, and cosmetic products. Revenue is generated from ingredient sales to B2B customers (cosmetic companies, food and beverage manufacturers).
2. Cosmetic Ingredient Licensing: OLIGEN (oleocanthal) is licensed as an ingredient to cosmetic companies for use in skincare formulations. The INCI approval enables cosmetic manufacturers to label and incorporate OLIGEN in existing and new products, generating royalty/licensing revenue per unit or via supply agreements.
3. Direct-to-Consumer Skincare (SUPER-OLI): Oleolive's debut consumer product, SUPER-OLI, is a novel skincare oil marketed as the highest concentration of phenolic compounds (oleocanthal and hydroxytyrosol) in a commercially available product, sold directly to consumers via e-commerce.
4. Government-Funded R&D (NIH/DoD): Oleolive generates non-dilutive funding through Small Business Technology Transfer (STTR) and Small Business Innovation Research (SBIR) grants from the National Cancer Institute, National Institute on Aging, National Heart, Lung, and Blood Institute, and the Department of Defense to fund therapeutic drug development programs.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Oleolive is a biotechnology company that develops functional molecules from discovery to commercial scale. Its flagship commercial product is Oligen, a standardized olive polyphenol ingredient (containing oleocanthal and oleacein) sold to food, beverage, and cosmetic manufacturers, and used in its own SUPER-OLI direct-to-consumer skincare line. The company also operates a therapeutic drug pipeline spanning glioblastoma, Alzheimer's disease, pulmonary fibrosis, and trauma hemorrhage, funded primarily through NIH and DoD grants.

Product overview

Oleolive is a biotech company that develops functional molecules from discovery to commercial scale across nutrition, oncology, neurology, fibrosis, and acute care. The commercialized flagship product is Oligen®, an olive polyphenol dietary ingredient developed in partnership with Applied Food Sciences, targeting joint health, heart health, and healthy aging. The therapeutic pipeline includes OL TL1 for glioblastoma, OL 003 for Alzheimer's disease, OL JC2 for pulmonary fibrosis, and Agile PRP for hemorrhage control.

Differentiator

Problem solved

Functional benefit

Brands

• SUPER-OLI: Novel skincare oil that harnesses health benefits of phenolics found in extra virgin olive oil, with the highest concentration of phenolic compounds like oleocanthal and hydroxytyrosol in a commercially available product.
• Oligen

Products and services

• Oligen® Flagship olive polyphenol dietary ingredient standardized to contain oleocanthal and oleacein, marketed to support joint health, heart health, and healthy aging. Sold as a B2B ingredient to food, beverage, and cosmetic manufacturers worldwide through the Applied Food Sciences partnership.
• SUPER-OLI Skincare Oil Novel premium skincare oil marketed as the highest concentration of phenolic compounds (oleocanthal and hydroxytyrosol) in a commercially available product, sold directly to individual consumers via the super-oli.com e-commerce storefront.
• OL-TL1 (Propentofylline) Glioblastoma Program Investigational repurposed small-molecule drug (Propentofylline) being developed as a chemosensitizer for glioblastoma tumors in collaboration with Mayo Clinic, funded by an NCI Phase I STTR grant.
• OL-003 Alzheimer's Disease Program Investigational dual PPAR delta and gamma agonist targeting neuroinflammation, insulin resistance, and metabolic dysfunction in Alzheimer's disease, advanced through NIA Phase II STTR funding with Auburn University.
• OL-JC2 Pulmonary Fibrosis Program

Quantifiable outcome

• Oleolive's proprietary process generates up to 95+% pure oleocanthal (OLIGEN) — described as one of the most potent olive phenolics known, with anti-oxidant, anti-inflammatory, anti-fungal, and overall therapeutic properties.
• +2 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Applied Food Sciences, Inc.flagshipStrategic or Co-development Partner · 3 November 2025Applied Food Sciences and Oleolive partnered to develop Oligen, an olive extract ingredient standardized to contain oleocanthal and oleacein. The ingredient is marketed to support joint health, heart health, and healthy aging, and can be used in various food and beverage products. This is a co-development and commercial partnership, with Applied Food Sciences distributing the Oligen ingredient.
• University of Louisiana MonroecoreStrategic or Co-development PartnerOleolive partnered with Dr. Khalid El Sayed's laboratory at University of Louisiana Monroe for Triple Negative Breast Cancer research on Oleocanthal. Dr. El Sayed, a Medicinal Chemist and Professor at ULM, has published several studies on Oleocanthal's effects on TNBC, and Oleolive built upon this existing research to secure NCI funding. The collaboration is co-development in nature.
• Mayo CliniccoreStrategic or Co-development PartnerOleolive's Phase 1 STTR grant for glioblastoma chemosensitization (OL-TL1/Propentofylline) is conducted as a joint effort with the Mayo Clinic, leveraging clinical and research expertise for preclinical and translational development of the therapeutic candidate.
• Auburn UniversitycoreStrategic or Co-development PartnerOleolive's Phase 2 STTR grant for Alzheimer's disease (OL-003) is conducted as a joint effort with Auburn University, combining Oleolive's drug development capabilities with Auburn's academic research infrastructure to generate data required for FDA IND filing.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sabinsa: Large, established supplier of standardized herbal extracts, cosmeceuticals, and specialty nutraceutical ingredients with global distribution. Comparable ingredient categories and target customers, though Sabinsa operates at much greater scale and portfolio breadth.
• Indena: Italy-based global leader in botanical actives and high-purity phytosome ingredients for pharma, nutraceutical, and personal care. Comparable in the high-purity botanical extract positioning that Oleolive claims for OLIGEN.
• Kemin Industries: Privately held global ingredient manufacturer serving human nutrition, animal health, and personal care. Overlapping customer base in B2B ingredient supply with Oleolive's Oligen line, though with a far broader portfolio.

Direct peers

• Novocure: Commercial-stage oncology company with an FDA-approved device therapy for glioblastoma and other solid tumors. Comparable as a focused developer of novel glioblastoma therapies, providing a benchmark for therapeutic commercial trajectory in Oleolive's OL-TL1 indication.
• Applied Food Sciences: Oleolive's flagship B2B partner and a leading US-based supplier of branded botanical extracts and functional ingredients for beverage, supplement, and food manufacturers. Comparable as both a channel partner and a direct competitor in the B2B ingredient space.
• Gencor: Global ingredient supplier specializing in branded, clinically studied botanical extracts for the nutraceutical and functional food markets. Directly comparable business model to Oleolive's Oligen B2B ingredient line.
• EuroMed (Euromed S.A.): Producer of standardized olive polyphenol extracts (including hydroxytyrosol and oleuropein) under the Mediteanox and Hidrox brands for supplements, functional food, and cosmetics. Comparable in product category and target customers to Oleolive's Oligen.
• CreAgri: US-based developer of olive-derived hydroxytyrosol ingredients and supplements. Most direct competitor in olive polyphenol ingredient manufacturing, serving overlapping nutraceutical and cosmetic end-markets.

Emerging players

• INmune Bio: Small clinical-stage biotech developing immune-targeted therapies for Alzheimer's and other neurodegenerative diseases. Comparable scale and platform-company structure to Oleolive, with a similarly grant-supported development path.
• Pliant Therapeutics: Clinical-stage biopharma developing integrin-targeted therapies for idiopathic pulmonary fibrosis and other fibrotic diseases. Most directly comparable peer for Oleolive's OL-JC1/JC2 inhalable anti-fibrotic program, though at a more advanced clinical stage.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/oleoliveUS
• LinkedInlinkedin.com/company/oleolive

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oleolive